Ironwood Pharmaceuticals, Inc. (IRWD) Q2 FY26 Earnings Call

$282.3 million Q2 Linzess sales and 30%+ 2026 growth support raised guidance [7].

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-06
Length33 minutes
EPS$0.31
EPS consensus$0.26
Revenue$113.0M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All IRWD earnings ยท Back to IRWD overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.